Skip to main content
PLOS One logoLink to PLOS One
. 2023 Sep 15;18(9):e0291589. doi: 10.1371/journal.pone.0291589

Ion exchange chromatography as a simple and scalable method to isolate biologically active small extracellular vesicles from conditioned media

Ricardo Malvicini 1,2,3,4,*, Diego Santa-Cruz 1, Anna Maria Tolomeo 3,4,5, Maurizio Muraca 2,3,4, Gustavo Yannarelli 1,#, Natalia Pacienza 1,#
Editor: Elia Bari6
PMCID: PMC10503763  PMID: 37713424

Abstract

In the last few years, extracellular vesicles (EVs) have become of great interest due to their potential as biomarkers, drug delivery systems, and, in particular, therapeutic agents. However, there is no consensus on which is the best way to isolate these EVs. The choice of the isolation method depends on the starting material (i.e., conditioned culture media, urine, serum, etc.) and their downstream applications. Even though there are numerous methods to isolate EVs, few are compatible with clinical applications as they are not scalable. In the present work, we set up a protocol to isolate EVs from conditioned media by ion exchange chromatography, a simple, fast, and scalable method, suitable for clinical production. We performed the isolation using an anion exchange resin (Q sepharose) and eluted the EVs using 500 mM NaCl. We characterized the elution profile by measuring protein and lipid concentration, and CD63 by ELISA. Moreover, we immunophenotyped all the eluted fractions, assessed the presence of TSG101, calnexin, and cytochrome C by western blot, analyzed nanoparticle size and distribution by tRPS, and morphology by TEM. Finally, we evaluated the immunomodulatory activity in vitro. We found that most EVs are eluted and concentrated in a single peak fraction, with a mean particle size of <150nm and expression of CD9, CD63, CD81, and TSG101 markers. Moreover, sEVs in fraction 4 exerted an anti-inflammatory activity on LPS-stimulated macrophages. In summary, we set up a chromatographic, scalable, and clinically compatible method to isolate and concentrate small EVs from conditioned media, which preserves the EVs biological activity.

Introduction

In the last few years, extracellular vesicles smaller than 200 nm (sEVs) have drawn attention as they are implicated in numerous biological processes, including cell-to-cell communication, both in paracrine and endocrine fashions [1]. In particular, mesenchymal stromal cells-derived sEVs (MSC-sEVs) have been found to reproduce many of the beneficial biological activities of their parental cells, such as immunomodulatory, anti-inflammatory, antioxidant, and anti-apoptotic activities [25]. However, MSC-sEVs have several advantages compared to their parental cells, as they are non-living and non-replicating entities they do not have the capacity for ectopic colonization, and the risk of embolism after intravenous or intra-arterial administration is lower. Consequently, sEVs administration represents a safer and more attractive therapeutic approach [68]. In this sense, MSC-sEVs infusion has been used to treat different pathologies, such as acute myocardial infarction, acute kidney injury, inflammatory bowel disease, and autoimmune diseases, among others, in which the immune system plays a key role [5, 911]. sEVs are composed of a lipid bilayer with transmembrane proteins enclosing cytoplasmic components, resulting in complex biological entities that carry different molecules, including lipids, proteins, and nucleic acids (miRNA, mRNA, lncRNA, among many others) [1214]. In this sense, it has been demonstrated that the cell secretome and the sEVs cargo are greatly influenced by the environment and the cell culture conditions [15]. Moreover, the characteristics and activity of a certain sEV preparation will also depend on the chosen isolation method, as it directly determines which EV subpopulations are isolated, and also, which other components are co-isolated (such as protein aggregates, RNAs, etc.) based on each method isolation principle [1618]. Currently, several different methods are employed, including ultracentrifugation, density gradient centrifugation, size exclusion chromatography, polyethylene glycol precipitation, and tangential flow filtration (TFF). Until now, the most widely diffused methods to isolate EVs at lab-scale are ultracentrifugation and density gradients. However, these methods do not allow to process large volumes of culture media and, therefore, are unsuitable for the large-scale manufacturing required for clinical applications. In the sense, TFF, asymmetrical flow field-fractionation (AF4) and IEX are regarded as promising methods for the large-scale EV isolation, as they allow to process large volumes of conditioned media, are feasibly automated and are cost-effective [19, 20].

MSC-derived sEVs isolated by IEX have shown beneficial effects in animal models of traumatic brain injury, status epilepticus, LPS-induced systemic inflammation, arterial stiffness and hypertension, and allergic airway inflammation [2125]. However, most of these reports do not provide a detailed isolation methodology. Moreover, none of them characterized the sEVs in compliance with ISEV criteria [26] and selected the sEV fraction based on protein content or CD63 expression.

In our current work, we optimized and fully characterized a previously described method to isolate MSC-derived sEVs from conditioned media by anion exchange chromatography using a Q Sepharose resin [23, 27]. As EVs have a negatively charged surface or zeta potential, they are first retained on the cationic resin by electrostatic forces and then eluted by increasing the ionic strength (salt concentration) of the buffer. This method is characterized for being soft (i.e., sEVs are not subjected to extreme centrifugal forces) and scalable allowing the processing of large amounts of conditioned media and making it compatible with clinical production. The performance of this isolation method was assessed: (I) by characterizing the biochemical profile of the eluted fractions; (II) by evaluating the presence of sEVs by transmission electron microscopy; (III) by characterizing the size and distribution by tRPS analysis; (IV) by detecting tetraspanins (CD9, CD63, and CD81) and the exosome marker TSG101; and, (V) by evaluating the biological activity of the eluted fractions. As a result, most of the MSC-sEVs are eluted and concentrated in a single peak fraction, rendering a pure and biologically active sEV preparation.

Materials and methods

The protocol described in this peer-reviewed article is published on protocols.io, dx.doi.org/10.17504/protocols.io.3byl4b71zvo5/v1 and is included for printing as S1 File with this article.

Expected results and discussion

MSC-sEVs isolation and elution profile characterization

Conditioned media (60-200mL) was subjected to ion exchange chromatography for EV isolation, and 8 fractions of 1 mL each were obtained (Fig 1). In order to characterize the elution profile and evaluate the presence of MSC-sEVs, we analyzed each fraction by tRPS and TEM. tRPS analysis was only possible in fractions 2 to 5, as in the other fractions no particles were detected (Fig 2A). The distribution parameters (mean, mode, D10, D50, and D90) of each fraction are summarized in the S1 Table. In all cases, the mean diameter was <200 nm, suggesting the presence of only sEVs. Moreover, we found that the particle number peaked at fraction 4 (Fig 2B).

Fig 1. Ion exchange chromatography protocol.

Fig 1

Schematic and summarized protocol for the isolation of sEVs from conditioned media by ion exchange chromatography.

Fig 2. Size and distribution analysis of the different fractions.

Fig 2

(A) Representative size distribution profile of fractions 2 to 5 measured by tunable resistive pulse sensing (tRPS). (B) Mean particle concentration for each fraction (mean±SD from five independent samples).

However, when analysing the different fractions by TEM, vesicular structures were found in fractions 3 and 4, indicating that EVs are only present in these two fractions (Fig 3). To further characterize the elution profile, we evaluated the protein, lipid, and nucleic acids concentration in each fraction.

Fig 3. Transmission electron microscopy (TEM) characterization.

Fig 3

Fractions 2 to 5, in which particles were detected, were subjected to TEM analysis. Vesicular structures were only found in fractions 3 and 4. Inset: close-up view of a vesicle.

We found no proteins in fractions 1 and 2, and they begin to elute in fraction 3, peaking at fraction 5, and then steadily decreasing between fractions 6 to 8 (Fig 4A). Moreover, silver staining of the different fractions showed the same elution profile as BCA analysis, with proteins peaking in fraction 5, while the protein pattern revealed an enrichment of proteins bigger than 37KDa (Fig 4B). Moreover, almost a 50-fold protein concentration was achieved, when comparing fraction 4 to the conditioned media. Regarding the lipids, the highest amount of lipids was found in fraction 4. This may be due to the presence of EVs, as demonstrated by transmission electron microscopy imaging, which confirms the presence of vesicles only in fractions 3 and 4 (Fig 4C). Finally, we evaluated the expression of CD63 by a sandwich ELISA, which allows detecting particles with more than one molecule of CD63 (free CD63 is not detected). We found that there was no CD63 in fractions 1 and 2, it then peaked in fraction 4, and decreased from fractions 5 to 8 (Fig 4D). These results show that, independently of the input volume, the method is robust and reproducible, as the same elution profile is observed (for all the isolations performed) for the proteins, lipids and CD63. As expected, the yield of proteins and lipids do vary according to the input volume. Finally, to evaluate whether the proteins were free or bound to the EVs, fraction 4 was dialyzed with a 300KDa dialysis membrane and then an SDS-PAGE followed by silver staining was performed. We found that the protein pattern before and after the dialysis is comparable, thus confirming that most of the proteins are bound to the EVs (Fig 4E).

Fig 4. Biochemical characterization of the eluted fractions.

Fig 4

Five independent EV isolations from conditioned media (volume ranging between 60-200mL) were performed. (A) Protein concentration was measured by BCA. (B) The protein pattern in the different fractions was evaluated by SDS-PAGE followed by silver staining. (C) Lipid concentration was assessed by sulfo-phospho-vanillin assay. (D) The presence of the exosome marker CD63 was assessed by ELISA. (E) The protein pattern in fraction 4 before and after a 300KDa dialysis was evaluated by SDS-PAGE followed by silver staining.

We also evaluated the presence of the tetraspanins CD9, CD63, and CD81 in all eight fractions, by flow cytometry. Interestingly, all three tetraspanins showed a very similar elution profile among them and also with the CD63 elution profile evaluated by ELISA, as these markers were not detected in fractions 1 and 2, then peaked in fraction 4, and then decreased to almost undetectable levels from fraction 5 to 8. The major difference among the markers was that CD63 was the most abundant marker (almost 6-fold, with respect to CD9 and CD81) and it was also found in fraction 3, while CD9 and CD81 were not (Fig 5A). Finally, we evaluated the presence of the intravesicular exosome marker TSG101 in the different fractions. Remarkably, TSG101 elution profile corresponded to that of CD9, CD63, and CD81, as it was absent in fractions 1 and 2, peaked at fraction 4, decreased in fraction 5 and became undetectable in fractions 6 to 8 (Fig 5B). These results indicate that MSC-sEVs are mostly eluted as a single peak in fraction 4, with a minor fraction of them also eluted in fraction 3. Moreover, to rule out any possible contamination with mitochondria or endoplasmic reticulum derived vesicles, we evaluated the presence of cytochrome C and calnexin by western blot. We found that these proteins were present in MSCs, but were absent in all the eluted fractions (Fig 5C). The protein, lipid, and CD63 elution profiles from five different independent preparations, demonstrate that the method is robust and reproducible, even if processing different volumes of culture media. The protein recovery rate, calculated as: (fraction volume x fraction protein concentration) x100/(input volume x input protein concentration), is usually between 4–18% (mean±2SD). It is important to consider that EVs are eluted in a high salt concentration buffer, which may affect downstream processing. As EVs are significantly concentrated during the isolation, it is often possible to dilute them with a buffer without NaCl to adjust the final salt concentration. Otherwise, EVs can be desalted by filtration using 100KDa Amicon filters.

Fig 5. Exosome markers analysis.

Fig 5

(A) The presence of the tetraspanins CD9, CD63, and CD81, which are considered exosome markers, were assessed by flow cytometry. (B) The intravesicular protein TSG101 was assessed by western blot and the optical density was quantified using Image J software. (C) The absence of cytochrome C and calnexin in all the eluted fractions was confirmed by western blot.

Additionally, we further characterized the different fractions by assessing the presence of MSC-related markers, adhesion molecules, and immunological markers by flow cytometry. Regarding MSC-related markers, we found that fraction 4 was positive for SSEA4 (detected also in fractions 3 and 5), CD44 (detected also in fractions 5 and 6) and CD105, while negative for HLA-1 (which was slightly positive in fraction 3), CD45 and HLA-DR (S1A Fig). Regarding the adhesion molecules, CD29 was highly expressed in fraction 4 (and was also detectable in fractions 3, 5 and 6), while CD41b, CD49e, CD62p, CD133, CD142 and CD146 were barely detectable (S1B Fig). Finally, immunological markers were almost not detectable in any fraction, except for low levels of CD3 (fractions 1, 2 and 3) and CD56 (all fractions except for fraction 4 and 6) (S1C Fig). In summary, surface protein expression in sEVs reflects that of the parent cells.

Finally, we evaluated the biological activity of the different eluted fractions for each independent isolation performed, to also test the reproducibility and robustness of the method. For this purpose, we employed a standardized in vitro assay that assesses EVs anti-inflammatory activity in LPS-stimulated macrophages [19, 20]. As shown in Fig 6A, macrophages significantly increased nitrite production after LPS stimulation, while the addition of dexamethasone significantly inhibited this response (-68 ± 19%; p<0.001). We found that fractions 3 and 4 exerted an anti-inflammatory activity, as they significantly inhibited nitrite production by about 10–30% and 35–75% (p<0.01 and p<0.001, respectively, respect to LPS), while the other fractions did not show any significant biological activity (Fig 6B). Even though the relative activity of fractions 3 and 4 varied between the replicates, the highest biological activity was always retrieved in fraction 4. Interestingly, the anti-inflammatory activity of the elution profile corresponds with the elution profile for CD63 and TSG101.

Fig 6. Ion exchange chromatography yields biologically active sEVs.

Fig 6

The anti-inflammatory activity of the different fractions was tested on LPS-stimulated RAW264.7 macrophages. (A) Nitric oxide production was used as an M1 polarization index. In culture media, nitric oxide turns into nitrite, which was quantified by Griess reaction. Representative results from one independent isolation. (B) Activity of the different fractions calculated as the percentage of nitrite production inhibition with respect to LPS for each independent isolation. Results from three independent experiments. #p<0.01; ‡p<0.001 after One-Way ANOVA with Tukey’s post test.

Conclusion

In this work, we optimized and fully characterized a simple and soft method for sEV isolation using anion exchange chromatography, where sEVs are eluted with 500 mM NaCl. The elution profile of the EVs was characterized not only at protein and lipid level, but also by assessing the presence of specific markers, which indicate that EVs are concentrated and eluted mainly as a single fraction. At lab-scale, the ion exchange chromatography allows the isolation of sEVs from up to 200 ml of conditioned media, but as it is a scalable method, it would allow the isolation of sEVs from litres of conditioned media, compatible with clinical applications. Moreover, as it is a soft method and no extreme centrifugal forces are needed to isolate the EVs, only the gravity force, their morphology is preserved, contributing to their stability and retention of their biological activity, as demonstrated by the anti-inflammatory effect on LPS-stimulated macrophages. Our results suggest that EVs are mostly retrieved in fraction 4, in which the highest amount of CD9, CD63, CD81 and TSG101 are found as well as the highest biological activity is observed. Thus, it would be advisable to work only with fraction 4, without pooling the different eluted fractions. So far, the isolation methods regarded as compatible with the large-scale production of sEV are TFF, AF4 and IEX. In this regard, the present ion exchange chromatography protocol provides proof of concept of a methodology that is feasibly scalable and that allows the isolation and concentration of biologically active EVs in just 1mL. Finally, it should be useful for the isolation of sEV from large volumes of conditioned media, contributing to translating EV therapy from basic research into the clinic.

Supporting information

S1 File. Ion exchange chromatography protocol for the isolation of extracellular vesicles from conditioned media.

Step-by-step protocol, also available on protocols.io.

(PDF)

S2 File. Materials and methods related to the production, quantification and characterization of the EVs.

(DOCX)

S3 File. Raw gel/blots images.

Uncropped and unadjusted images of the blots for TSG101, calnexin and Cytochrome C and the gels after silver-staining are provided.

(PDF)

S4 File. MacsPlex flow cytometry gating strategy.

A representative gating strategy for the analysis of the different sample is provided.

(PDF)

S5 File. MacsPlex flow cytometry raw data.

Representative RAW data (mean fluorescence intensity) from the MacsPlex analysis from a single experiment is provided.

(TXT)

S1 Fig. sEV surface proteins assessment.

The presence of surface proteins was assessed by flow cytometry using the MACSPlex kit. MSC related proteins are depicted in (A), adhesion molecules are shown in (B) and immunological related proteins are shown in (C).

(DOCX)

S1 Table. Size and distribution parameters.

Mean size, mode, D10, D50 and D90 parameters from the tRPS analysis for fractions 2, 3, 4 and 5.

(DOCX)

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

This work was supported by the Fondo para la Investigación Científica y Tecnológica (FONCyT) under grants PICT-2019-00659 and PICT 2020-SERIE A-03292 (held by NP) and by Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) under grant PIP-2015-2017 (11220150100188CO) held by GY. This work was also supported by CONICET under a PUE grant (22920160100101CO) and by Consorzio per la Ricerca Sanitaria (LIFELAB Program) (grant no. DGR1017, July 17, 2018, held by MM), which also funded R. Malvicini air tickets from Argentina to Italy”. The role of the founders should read as follows: “MM, GY and NP took part in the data curation, supervision and writing of the original manuscript and the revised version. GY and NP also took part in the decision to publish, conceptualization and data analysis.

References

  • 1.Liang X, Ding Y, Zhang Y, Tse HF, Lian Q. Paracrine mechanisms of mesenchymal stem cell-based therapy: Current status and perspectives. Cell Transplantation. Cognizant Communication Corporation; 2014. pp. 1045–1059. doi: 10.3727/096368913X667709 [DOI] [PubMed] [Google Scholar]
  • 2.Yáñez-Mó M, Siljander PR-M, Andreu Z, Bedina Zavec A, Borràs FE, Buzas EI, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015;4: 27066. doi: 10.3402/jev.v4.27066 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Doeppner TR, Herz J, Görgens A, Schlechter J, Ludwig A-K, Radtke S, et al. Extracellular Vesicles Improve Post-Stroke Neuroregeneration and Prevent Postischemic Immunosuppression. Stem Cells Transl Med. 2015;4: 1131–1143. doi: 10.5966/sctm.2015-0078 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.HE J, WANG Y, SUN S, YU M, WANG C, PEI X, et al. Bone marrow stem cells-derived microvesicles protect against renal injury in the mouse remnant kidney model. Nephrology. 2012;17: 493–500. doi: 10.1111/j.1440-1797.2012.01589.x [DOI] [PubMed] [Google Scholar]
  • 5.Bruno S, Grange C, Deregibus MC, Calogero RA, Saviozzi S, Collino F, et al. Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol. 2009;20: 1053–1067. doi: 10.1681/ASN.2008070798 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Lener T, Gimona M, Aigner L, Börger V, Buzas E, Camussi G, et al. Applying extracellular vesicles based therapeutics in clinical trials—An ISEV position paper. J Extracell Vesicles. 2015;4. doi: 10.3402/jev.v4.30087 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Yeo RWY, Lai RC, Zhang B, Tan SS, Yin Y, Teh BJ, et al. Mesenchymal stem cell: An efficient mass producer of exosomes for drug delivery. Advanced Drug Delivery Reviews. Adv Drug Deliv Rev; 2013. pp. 336–341. doi: 10.1016/j.addr.2012.07.001 [DOI] [PubMed] [Google Scholar]
  • 8.Furlani D, Ugurlucan M, Ong LL, Bieback K, Pittermann E, Westien I, et al. Is the intravascular administration of mesenchymal stem cells safe?. Mesenchymal stem cells and intravital microscopy. Microvasc Res. 2009;77: 370–376. doi: 10.1016/j.mvr.2009.02.001 [DOI] [PubMed] [Google Scholar]
  • 9.Shigemoto-Kuroda T, Oh JY, Kim D ki, Jeong HJ, Park SY, Lee HJ, et al. MSC-derived Extracellular Vesicles Attenuate Immune Responses in Two Autoimmune Murine Models: Type 1 Diabetes and Uveoretinitis. Stem Cell Reports. 2017;8: 1214–1225. doi: 10.1016/j.stemcr.2017.04.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Tolomeo AM, Castagliuolo I, Piccoli M, Grassi M, Magarotto F, De Lazzari G, et al. Extracellular Vesicles Secreted by Mesenchymal Stromal Cells Exert Opposite Effects to Their Cells of Origin in Murine Sodium Dextran Sulfate-Induced Colitis. Front Immunol. 2021;12. doi: 10.3389/fimmu.2021.627605 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Wendt S, Goetzenich A, Goettsch C, Stoppe C, Bleilevens C, Kraemer S, et al. Evaluation of the cardioprotective potential of extracellular vesicles–a systematic review and meta-analysis. Sci Rep. 2018;8: 1–14. doi: 10.1038/s41598-018-33862-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Théry C. Exosomes: Secreted vesicles and intercellular communications. F1000 Biology Reports. 2011. doi: 10.3410/B3-15 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.György B, Szabó TG, Pásztói M, Pál Z, Misják P, Aradi B, et al. Membrane vesicles, current state-of-the-art: Emerging role of extracellular vesicles. Cellular and Molecular Life Sciences. Springer; 2011. pp. 2667–2688. doi: 10.1007/s00018-011-0689-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Colombo M, Raposo G, Théry C. Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles. Annu Rev Cell Dev Biol. 2014;30: 255–289. doi: 10.1146/annurev-cellbio-101512-122326 [DOI] [PubMed] [Google Scholar]
  • 15.Witwer KW, Van Balkom BWM, Bruno S, Choo A, Dominici M, Gimona M, et al. Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. J Extracell Vesicles. 2019;8. doi: 10.1080/20013078.2019.1609206 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Buschmann D, Kirchner B, Hermann S, Märte M, Wurmser C, Brandes F, et al. Evaluation of serum extracellular vesicle isolation methods for profiling miRNAs by next-generation sequencing. J Extracell Vesicles. 2018;7: 1481321. doi: 10.1080/20013078.2018.1481321 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Brennan K, Martin K, FitzGerald SP, O’Sullivan J, Wu Y, Blanco A, et al. A comparison of methods for the isolation and separation of extracellular vesicles from protein and lipid particles in human serum. Sci Rep. 2020;10: 1–13. doi: 10.1038/s41598-020-57497-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Tauro BJ, Greening DW, Mathias RA, Ji H, Mathivanan S, Scott AM, et al. Comparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived exosomes. Methods. 2012;56: 293–304. doi: 10.1016/j.ymeth.2012.01.002 [DOI] [PubMed] [Google Scholar]
  • 19.Staubach S, Bauer FN, Tertel T, Börger V, Stambouli O, Salzig D, et al. Scaled preparation of extracellular vesicles from conditioned media. Adv Drug Deliv Rev. 2021;177: 113940. doi: 10.1016/j.addr.2021.113940 [DOI] [PubMed] [Google Scholar]
  • 20.Monguió-Tortajada M, Gálvez-Montón C, Bayes-Genis A, Roura S, Borràs FE. Extracellular vesicle isolation methods: rising impact of size-exclusion chromatography. Cell Mol Life Sci. 2019;76: 2369–2382. doi: 10.1007/s00018-019-03071-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Longa Q, Upadhya D, Hattiangady B, Kim DK, An SY, Shuai B, et al. Intranasal MSC-derived A1-exosomes ease inflammation, and prevent abnormal neurogenesis and memory dysfunction after status epilepticus. Proc Natl Acad Sci U S A. 2017;114: E3536–E3545. doi: 10.1073/pnas.1703920114 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Kim DK, Nishida H, An SY, Shetty AK, Bartosh TJ, Prockop DJ. Chromatographically isolated CD63+CD81+ extracellular vesicles from mesenchymal stromal cells rescue cognitive impairments after TBI. Proc Natl Acad Sci U S A. 2016;113: 170–175. doi: 10.1073/pnas.1522297113 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Pacienza N, Lee RH, Bae EH, Kim D ki, Liu Q, Prockop DJ, et al. In Vitro Macrophage Assay Predicts the In Vivo Anti-inflammatory Potential of Exosomes from Human Mesenchymal Stromal Cells. Mol Ther—Methods Clin Dev. 2019;13: 67–76. doi: 10.1016/j.omtm.2018.12.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Fang S Bin, Zhang HY, Wang C, He BX, Liu XQ, Meng XC, et al. Small extracellular vesicles derived from human mesenchymal stromal cells prevent group 2 innate lymphoid cell-dominant allergic airway inflammation through delivery of miR-146a-5p. J Extracell vesicles. 2020;9. doi: 10.1080/20013078.2020.1723260 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Feng R, Ullah M, Chen K, Ali Q, Lin Y, Sun Z. Stem cell-derived extracellular vesicles mitigate ageing-associated arterial stiffness and hypertension. J Extracell vesicles. 2020;9. doi: 10.1080/20013078.2020.1783869 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7. doi: 10.1080/20013078.2018.1535750 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Malvicini R, Santa-Cruz D, De Lazzari G, Tolomeo AM, Sanmartin C, Muraca M, et al. Macrophage bioassay standardization to assess the anti-inflammatory activity of mesenchymal stromal cell-derived small extracellular vesicles. Cytotherapy. 2022;24. doi: 10.1016/j.jcyt.2022.05.011 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Elia Bari

13 Jul 2023

PONE-D-23-17535Ion exchange chromatography as a simple and scalable method to isolate biologically active small extracellular vesicles from conditioned mediaPLOS ONE

Dear Dr. Malvicini,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Aug 27 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Elia Bari

Academic Editor

PLOS ONE

Comments from PLOS Editorial Office: We note that one or more reviewers has recommended that you cite specific previously published works. As always, we recommend that you please review and evaluate the requested works to determine whether they are relevant and should be cited. It is not a requirement to cite these works. We appreciate your attention to this request.

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following financial disclosure:

“This work was supported by the Fondo para la Investigación Científica y Tecnológica (FONCyT) under grants PICT-2019-00659 and PICT 2020-SERIE A-03292 (held by NP) and by Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) under grant PIP-2015-2017 (11220150100188CO) held by GY. This work was also supported by CONICET under a PUE grant (22920160100101CO) and by Consorzio per la Ricerca Sanitaria (LIFELAB Program) (grant no. DGR1017, July 17, 2018).”

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

3. Thank you for stating the following in the Acknowledgments Section of your manuscript:

“We are grateful to L.i.f.e.L.a.b. Program, Consorzio per la Ricerca Sanitaria (CORIS) for funding R. Malvicini air tickets from Argentina to Italy.”

We note that you have provided funding information that is currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

“This work was supported by the Fondo para la Investigación Científica y Tecnológica (FONCyT) under grants PICT-2019-00659 and PICT 2020-SERIE A-03292 (held by NP) and by Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) under grant PIP-2015-2017 (11220150100188CO) held by GY. This work was also supported by CONICET under a PUE grant (22920160100101CO) and by Consorzio per la Ricerca Sanitaria (LIFELAB Program) (grant no. DGR1017, July 17, 2018).”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

4. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

5. Please amend either the abstract on the online submission form (via Edit Submission) or the abstract in the manuscript so that they are identical.

6. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

7. We note you have not yet provided a protocols.io PDF version of your protocol and/or a protocols.io DOI. When you submit your revision, please provide a PDF version of your protocol as generated by protocols.io (the file will have the protocols.io logo in the upper right corner of the first page) as a Supporting Information file. The filename should be S1_file.pdf, and you should enter “S1 File” into the Description field. Any additional protocols should be numbered S2, S3, and so on. Please also follow the instructions for Supporting Information captions [https://journals.plos.org/plosone/s/supporting-information#loc-captions]. The title in the caption should read: “Step-by-step protocol, also available on protocols.io.”

Please assign your protocol a protocols.io DOI, if you have not already done so, and include the following line in the Materials and Methods section of your manuscript: “The protocol described in this peer-reviewed article is published on protocols.io (https://dx.doi.org/10.17504/protocols.io.[...]) and is included for printing purposes as S1 File.” You should also supply the DOI in the Protocols.io DOI field of the submission form when you submit your revision.

If you have not yet uploaded your protocol to protocols.io, you are invited to use the platform’s protocol entry service [https://www.protocols.io/we-enter-protocols] for doing so, at no charge. Through this service, the team at protocols.io will enter your protocol for you and format it in a way that takes advantage of the platform’s features. When submitting your protocol to the protocol entry service please include the customer code PLOS2022 in the Note field and indicate that your protocol is associated with a PLOS ONE Lab Protocol Submission. You should also include the title and manuscript number of your PLOS ONE submission.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does the manuscript report a protocol which is of utility to the research community and adds value to the published literature?

Reviewer #1: No

Reviewer #2: Yes

**********

2. Has the protocol been described in sufficient detail?

To answer this question, please click the link to protocols.io in the Materials and Methods section of the manuscript (if a link has been provided) or consult the step-by-step protocol in the Supporting Information files.

The step-by-step protocol should contain sufficient detail for another researcher to be able to reproduce all experiments and analyses.

Reviewer #1: Partly

Reviewer #2: No

**********

3. Does the protocol describe a validated method?

The manuscript must demonstrate that the protocol achieves its intended purpose: either by containing appropriate validation data, or referencing at least one original research article in which the protocol was used to generate data.

Reviewer #1: No

Reviewer #2: No

**********

4. If the manuscript contains new data, have the authors made this data fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the article presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please highlight any specific errors that need correcting in the box below.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The manuscript (PONE-D-23-17535) entitled "Ion exchange chromatography as a simple and scalable method to isolate biologically active small extracellular vesicles from conditioned media" reports a method for isolating small extracellular vesicles (sEVs) from conditioned media utilizing anion exchange chromatography (AEX). The isolated sEVs were comprehensively characterized using different techniques. The manuscript is clearly written and easy to follow. However, given that this research focuses on the sEV isolation method, the study fails to provide any new or innovative approaches in the field, as the use of AEX with very similar protocol is already well-established for conditioned media (see Comment-2 in more detail). This has left no significant contribution or innovation from this study. Therefore, based on these grounds, it is recommended that the manuscript be rejected. Detailed comments are as follows.

Comment-1. Introduction section

In the introduction section (page 3-4), the authors discussed general isolation techniques of EVs and addressed the anion exchange chromatography (AEX) as a scalable and gentle method for EV isolation. The authors discussed that the mentioned EV isolation methods do not allow processing large volumes of culture media. This statement is not entirely true. For instance, tangential flow filtration (TFF) has been reported in several publications to isolate EVs from cell culture media. TFF does not require any chemical interaction unlike AEX and is also considered a gentle method for EV isolation due to the lack of chromatographic resins (similar to AF4). Pros and cons of each technique have been comprehensively reviewed in e.g. T. Liangsupree et al. (2021). Modern isolation and separation techniques for extracellular vesicles. Journal of Chromatography A, 1636, 461773.

To conclude, given that the highlights of this manuscript revolve around AEX being a scalable and gentle method for sEV isolation, the argument in the introduction is not strong enough to support why other techniques cannot be used instead of AEX. For instance, TFF and AF4 are also considered as soft techniques and automation is possible (unlike preparation AEX reported in this manuscript) and both techniques allow large scale separation and purification of EVs.

Comment-2. Expected Results and Discussion section

An almost identical protocol for isolation of biologically active sEVs from mesenchymal stromal cells has already been published elsewhere in 2020 (see below). Thus, as previously mentioned, as the main focus of this manuscript is sEV isolation, its novelty is compromised.

S. B. Fang et al. (2020). Small extracellular vesicles derived from human mesenchymal stromal cells prevent group 2 innate lymphoid cell-dominant allergic airway inflammation through delivery of miR-146a-5p. Journal of extracellular vesicles, 9(1), 1723260.

General comments to the method are given below:

1. Experiment details on MSC-sEVs isolation and elution profile characterization should (Page 5, MSC-sEVs isolation and elution profile characterization) should be part of Materials and Methods section and not in Expected Results and Discussion section.

2. It is reported that the column can be used for 200 ml of conditioned media. Extra information that could affect separation and yield, such as number of cells in the conditioned media, the times one prepared column can be used with satisfactory results (i.e., without losing its efficiency), should be given to claim that the method is reproducible especially when the column is manually prepared/packed.

3.What is the superiority of this method over other reported AEX methods also used for MSC derived EV isolation? The method reported in manuscript is laborious and requires over 4 hours to isolate EVs from 200 ml of condition media. Despite the fact that it is significantly shorter than ultracentrifugation, an AEX method that can process 1 L of conditioned media in less than 3 h has been reported (see N. Heath et al., (2018). Rapid isolation and enrichment of extracellular vesicle preparations using anion exchange chromatography. Scientific reports, 8(1), 5730).

A strong argumentative discussion is required to support the method reported in this manuscript.

4. The study reports the results from five independent samples, but no information on column-to-column reproducibility is provided.

Reviewer #2: The manuscript submitted by Ricardo Malvicini and the co-authors is devoted to the use of anion-exchange isolation of extracellular vesicles on Q-Sepharose.

The method proposed by the authors let them isolate the subfraction of sEV from a cell culture medium using a single chromatography step. The protocol is submitted to protocols.io, making it easily accessible to the readers.

The manuscript has several major and minor issues, which should be resolved before the manuscript might be accepted for publication.

1) The authors used the tRPS method for the sEV analysis. tRPS is first mentioned on p.5 of the pdf but is never deciphered. Also, the advantages and, disadvantages, limitations of the method are not discussed. This approach is not one of the most widely used for the characterization of sEV since this is obligatory for the manuscript

2) What is the protein with molecular mass between 50 and 70 kDa (Fig.4B, line 5)? It can be easily detected by trypsinolysis and MALDI of another mass-spectrometry approach. Whether this is serum albumin? If it is, whether these fractions contain sEV or are co-isolated with albumin during AEC on Q-Sepharose? The protein with ~250 kDa on line 5 can also be easily detected with any MS method.

Since the proteins in isolated fractions are easily distinguished, the basic proteomic investigation of fractions eluted from Q-Sepharose is highly recommended.

3) The authors state that "the highest amount of lipids was found in fraction 4, which corresponds to the presence of EVs," but this statement never provides evidence of EV-nature of this fraction.

4) The raw data of flow cytometry should be provided in the paper or the supplementary file

5) In the current form of the paper, the statement "the present ion exchange chromatography provides an alternative methodology that should be useful for the isolation of EVs" is not confirmed by experimental results.

Sincerely

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Sep 15;18(9):e0291589. doi: 10.1371/journal.pone.0291589.r002

Author response to Decision Letter 0


19 Aug 2023

Reviewer #1:

The manuscript (PONE-D-23-17535) entitled "Ion exchange chromatography as a simple and scalable method to isolate biologically active small extracellular vesicles from conditioned media" reports a method for isolating small extracellular vesicles (sEVs) from conditioned media utilizing anion exchange chromatography (AEX). The isolated sEVs were comprehensively characterized using different techniques. The manuscript is clearly written and easy to follow. However, given that this research focuses on the sEV isolation method, the study fails to provide any new or innovative approaches in the field, as the use of AEX with very similar protocol is already well-established for conditioned media (see Comment-2 in more detail). This has left no significant contribution or innovation from this study. Therefore, based on these grounds, it is recommended that the manuscript be rejected. Detailed comments are as follows.

Comment-1. Introduction section

In the introduction section (page 3-4), the authors discussed general isolation techniques of EVs and addressed the anion exchange chromatography (AEX) as a scalable and gentle method for EV isolation. The authors discussed that the mentioned EV isolation methods do not allow processing large volumes of culture media. This statement is not entirely true. For instance, tangential flow filtration (TFF) has been reported in several publications to isolate EVs from cell culture media. TFF does not require any chemical interaction unlike AEX and is also considered a gentle method for EV isolation due to the lack of chromatographic resins (similar to AF4). Pros and cons of each technique have been comprehensively reviewed in e.g. T. Liangsupree et al. (2021). Modern isolation and separation techniques for extracellular vesicles. Journal of Chromatography A, 1636, 461773.

To conclude, given that the highlights of this manuscript revolve around AEX being a scalable and gentle method for sEV isolation, the argument in the introduction is not strong enough to support why other techniques cannot be used instead of AEX. For instance, TFF and AF4 are also considered as soft techniques and automation is possible (unlike preparation AEX reported in this manuscript) and both techniques allow large scale separation and purification of EVs.

Answer: We thank the reviewer for his/her comments and agree with him/her. We aim to propose the anion exchange chromatography as an alternative method for the large-scale production of sEV to TFF and AF4, but these techniques are also valid as scalable isolation methods. We realized that we failed to conveyed this idea, so we have changed the introduction section accordingly, as follows: “In the sense, TFF, asymmetrical flow field-fractionation (AF4) and IEX are regarded as promising methods for the large-scale EV isolation, as they allow to process large volumes of conditioned media, are feasibly automated and are cost-effective (Monguió-Tortajada et al.; Staubach et al.)”

Comment-2. Expected Results and Discussion section

An almost identical protocol for isolation of biologically active sEVs from mesenchymal stromal cells has already been published elsewhere in 2020 (see below). Thus, as previously mentioned, as the main focus of this manuscript is sEV isolation, its novelty is compromised.

S. B. Fang et al. (2020). Small extracellular vesicles derived from human mesenchymal stromal cells prevent group 2 innate lymphoid cell-dominant allergic airway inflammation through delivery of miR-146a-5p. Journal of extracellular vesicles, 9(1), 1723260

Answer: We thank the reviewer for his/her comment. As we stated in the introduction section, we do not claim that this is a brand new protocol, but an optimized and fully characterized version of it. This protocol was used to successfully isolate EVs that were utilized in different animal models (Kim et al.; Pacienza et al.; Guan et al.; Feng et al.; Longa et al.; Fang et al.). However, to our knowledge, the methodology has not been fully characterized so far, as most works only provide a deficient characterization and only address protein concentration and CD63 expression in the fractions. Instead, in this work, and following the recommendations of the International Society for Extracellular Vesicles (ISEV), we performed an exhaustive characterization of the method and all the eluted fractions, by assessing the particle size and distribution (tRPS), morphology (TEM), protein and lipid quantification, EV positive (CD63, CD9, CD81, TSG101) and negative (Cytochrome C and calnexin) markers, EV surface markers and their biological activity. Moreover, we are providing a fully-detailed protocol, while in other works, only the general considerations are provided.

General comments to the method are given below:

1. Experiment details on MSC-sEVs isolation and elution profile characterization should (Page 5, MSC-sEVs isolation and elution profile characterization) should be part of Materials and Methods section and not in Expected Results and Discussion section.

Answer: We thank the reviewer for his/her comment, and we removed that paragraph from the Expected Results and Discussion section.

2. It is reported that the column can be used for 200 ml of conditioned media. Extra information that could affect separation and yield, such as number of cells in the conditioned media, the times one prepared column can be used with satisfactory results (i.e., without losing its efficiency), should be given to claim that the method is reproducible especially when the column is manually prepared/packed.

Answer: We thank the reviewer for his/her comment. We believe that the maximum input volume that a 4mL resin can process will vary depending on the input media. At the same time, the input media will vary depending on the culture conditions (time, stimulation, etc), the cell type cultured, the cellular density and other factors. In this sense, we performed the isolation of EVs derived from MSCs after 48h of culture in alpha-mem, without FBS. At the time of medium change to alpha-MEM, the cellular confluence was about 70% and at the end of the culture, we retrieved about 3x106 cells/T175cm2 flask.

In the different isolations, we processed between 60-200mL of conditioned media, that would be, the vesicles coming from 9-30x106 MSC. The results and the reproducibility of isolating different volumes of conditioned media can be seen in Figure 4A, C and D, where it can be observed the same elution profile, regardless of the input volume, but the yield varies according to the input volume. Moreover, we have also modified Figure 6 B, in which we show the anti-inflammatory activity of all the fractions, for each independent isolation performed, which also supports the reproducibility of the method.

To our knowledge and based on our results, the resin can be regenerated and reused up to two times, without losing its efficiency and maintaining the elution profile. Further re-utilizations would require validation.

We added the following paragraph in the supporting information file 2, MSCs culture section: “We performed 5 independent isolations and collected between 60-200mL of conditioned media, to evaluate the robustness and the reproducibility of the isolation protocol. The conditioned media collected contained the sEV produced by approximately 9-30x106 MSC or 3-10 T175 cm2 flasks”.

Also, we added the following sentences in the results section “These results show that, independently of the input volume, the method is robust and reproducible, as the same elution profile is observed (for all the isolations performed) for the proteins, lipids and CD63. As expected, the yield of proteins and lipids do vary according to the input volume.” And “We found that fractions 3 and 4 exerted an anti-inflammatory activity, as they significantly inhibited nitrite production by about 10-30% and 35-75% (p<0.01 and p<0.001, respectively, respect to LPS), while the other fractions did not show any significant biological activity (Fig 6B). Even though the relative activity of fractions 3 and 4 varied between the replicates, the highest biological activity was always retrieved in fraction 4.”

Moreover, we added the following sentence in the Figure’s 4 figure legend: “Five independent EV isolations from conditioned media (volume ranging between 60-200mL) were performed.”

3.What is the superiority of this method over other reported AEX methods also used for MSC derived EV isolation? The method reported in manuscript is laborious and requires over 4 hours to isolate EVs from 200 ml of condition media. Despite the fact that it is significantly shorter than ultracentrifugation, an AEX method that can process 1 L of conditioned media in less than 3 h has been reported (see N. Heath et al., (2018). Rapid isolation and enrichment of extracellular vesicle preparations using anion exchange chromatography. Scientific reports, 8(1), 5730).

A strong argumentative discussion is required to support the method reported in this manuscript.

Answer: The method described in this manuscript is intended for the isolation of low to middle volumes of culture media, in a research laboratory setting. If more than 200 mL of conditioned media need to be processed, multiple columns can be run in parallel, in order to speed up the isolation process, and the final fractions can be pooled. We agree with the reviewer that if the intention is to isolate sEV from large volumes of culture media (i.e. 1 liter or more) the protocol we propose should be adapted (for instance, by using a larger resin volume, by using a peristaltic pump, etc) for this aim. Nonetheless, the method we propose is not laborious, as it only requires to load the buffers and the conditioned media to the column, and then wait for it to elute.

Regarding the manuscript by Heath et al. the reviewer mentioned, Heath et al. claim that they isolate EVs from 1 L of conditioned media coming from an average of 7.8x108 HEK293T cells, which were cultured using Corning® 10 layer CellSTACKs® (Sigma) and they obtain 2.4x1011 particles. However, in our experimental settings, we are isolating EVs from 0.2 L of conditioned media, coming from an average of 3.5x107 mesenchymal stromal cells, using Corning T175 flasks, and we obtain a mean value of about 1x1011 particles. Moreover, HEK293T cells are an immortalized cell line, and it is well documented in literature that cell lines and tumor-derived cells produce more EVs than primary cells (Whiteside; Chin and Wang; Logozzi et al.). In this sense, it would be expected to isolate a higher amount of EVs from HEK293T cells than from mesenchymal stromal cells. However, in our conditions, we isolated almost half the EVs Heath et al. isolated (1x1011 particles vs 2.4x1011 particles), from 20 times less cells (3.5x107 vs 7.8x108 ) and 5 times less conditioned media (0.2L vs 1L). These results would suggest the superiority of our method in the efficiency to isolate extracellular vesicles from conditioned media. Moreover, the isolation method we propose would render the EV production process less expensive, than that proposed by Heath et al., as to obtain the same yield of EVs we need to process 2.5 times less conditioned media. From this analysis, it would seem that despite the fact that the protocol proposed by Heath et al. allows to process large volumes of conditioned media, it presents a low recovery and a low yield, compared to the protocol we propose. Finally, our protocol establishes the elution of EVs with 500mM of NaCl, while that of Heath et al. performs the elution with 890mM of NaCl. In this sense, the higher salt concentration and ionic force may compromise the integrity of the EVs and their biological activity, and therefore, limit their application. In this work, we demonstrate that EVs eluted with 500mM of NaCl retain their biological activity, as they are able to inhibit nitrite production in LPS-stimulated macrophages.

Despite all these considerations, in order to claim that an isolation protocol is superior and yields more vesicles than another protocol, the same culture conditions and the same cell type should be employed, so that the input media is the same.

4. The study reports the results from five independent samples, but no information on column-to-column reproducibility is provided.

Answer: The five independent samples are depicted in Figure 4, A, C and D, which show that the same elution profile is maintained regardless of the input volume and thus, confirming the reproducibility of the method. Moreover, we have also modified Figure 6 B, in which we show the anti-inflammatory activity of all the fractions, for each independent isolation performed, which provides evidence of the reproducibility of the method.

Reviewer #2:

The manuscript submitted by Ricardo Malvicini and the co-authors is devoted to the use of anion-exchange isolation of extracellular vesicles on Q-Sepharose.

The method proposed by the authors let them isolate the subfraction of sEV from a cell culture medium using a single chromatography step. The protocol is submitted to protocols.io, making it easily accessible to the readers.

The manuscript has several major and minor issues, which should be resolved before the manuscript might be accepted for publication.

1) The authors used the tRPS method for the sEV analysis. tRPS is first mentioned on p.5 of the pdf but is never deciphered. Also, the advantages and, disadvantages, limitations of the method are not discussed. This approach is not one of the most widely used for the characterization of sEV since this is obligatory for the manuscript

Answer: We thank the author for his/her comments. We clarified that tRPS stands for tunable resistive pulse sensing. Even though tRPS may not be the most diffused method to analyze particles’ size and distribution, it is recommended as a valid method of analysis by the international society for extracellular vesicles (ISEV), along with the Nanoparticle Tracking Analysis (NTA) and dynamic light scattering (DLS) (Théry et al.). Although it has some disadvantages, in our hands, this quantification method performs well. It is true that the quantification with the NTA gives a higher dynamic range than the tRPS, due to the fact that the membrane pore size limits the size of particles that can be quantified. However, as we filter the conditioned media by 0.22μM, we do not expect vesicles larger than this. Moreover, as it can be seen in Figure 2A, the whole peak is seen in fraction 4 and no particles bigger than 150nm are detected. The NP150 membrane that we used has an analysis range of 50-420nm, according to the manufacturers’ instructions.

We believe that discussion of the advantages, disadvantages and limitations of this method of analysis is out of the scope of this manuscript, as we are focusing on the isolation protocol.

2) What is the protein with molecular mass between 50 and 70 kDa (Fig.4B, line 5)? It can be easily detected by trypsinolysis and MALDI of another mass-spectrometry approach. Whether this is serum albumin? If it is, whether these fractions contain sEV or are co-isolated with albumin during AEC on Q-Sepharose? The protein with ~250 kDa on line 5 can also be easily detected with any MS method.

Since the proteins in isolated fractions are easily distinguished, the basic proteomic investigation of fractions eluted from Q-Sepharose is highly recommended.

Answer: We thank the reviewer for his/her comments. For EV production, MSCs are expanded in DMEM supplemented with FBS. When they reach 70% confluence, cells are subjected to 3 washes with PBS, in order to eliminate all the serum, and then the media is changed to alpha-MEM (chemically defined media with amino acids and no proteins) without FBS. Therefore, albumin contamination would be unlikely. Moreover, we have performed the proteomic analysis of fraction 4, but we focused on the whole preparation of sEV and not in specific bands. Of note, albumin was not detected in our preparations after the proteomic analysis.

3) The authors state that "the highest amount of lipids was found in fraction 4, which corresponds to the presence of EVs," but this statement never provides evidence of EV-nature of this fraction.

Answer: We thank the reviewer for this comment and we modified this sentence in the manuscript as follows “the highest amount of lipids was found in fraction 4. This may be due to the presence of EVs, as demonstrated by transmission electron microscopy imaging, which confirms the presence of vesicles only in fractions 3 and 4”.

4) The raw data of flow cytometry should be provided in the paper or the supplementary file.

Answer: We provide the both the dot plots, showing the gating strategy, and the RAW data of one representative experiment as Supplementary file 4 (S4 MacsPlex gating strategy) and Supplementary file 5 (S5 MacsPlex Raw Data).

5) In the current form of the paper, the statement "the present ion exchange chromatography provides an alternative methodology that should be useful for the isolation of EVs" is not confirmed by experimental results.

Answer: We modified this sentence in the manuscript as follows: “So far, the isolation methods regarded as compatible with the large-scale production of sEV are TFF, AF4 and IEX. In this regard, the present ion exchange chromatography protocol provides proof of concept of a methodology that is feasibly scalable and that allows the isolation and concentration of biologically active EVs in just 1mL. It should be useful for the isolation of sEV from large volumes of conditioned media, contributing to translate EV therapy from basic research into the clinics.”

Bibliography

Chin, Andrew R., and Shizhen Emily Wang. “Cancer-Derived Extracellular Vesicles: The ‘Soil Conditioner’ in Breast Cancer Metastasis?” Cancer Metastasis Reviews, vol. 35, no. 4, NIH Public Access, Dec. 2016, p. 669, doi:10.1007/S10555-016-9639-8.

Fang, Shu Bin, et al. “Small Extracellular Vesicles Derived from Human Mesenchymal Stromal Cells Prevent Group 2 Innate Lymphoid Cell-Dominant Allergic Airway Inflammation through Delivery of MiR-146a-5p.” Journal of Extracellular Vesicles, vol. 9, no. 1, J Extracell Vesicles, Jan. 2020, doi:10.1080/20013078.2020.1723260.

Feng, Rui, et al. “Stem Cell-Derived Extracellular Vesicles Mitigate Ageing-Associated Arterial Stiffness and Hypertension.” Journal of Extracellular Vesicles, vol. 9, no. 1, J Extracell Vesicles, Jan. 2020, doi:10.1080/20013078.2020.1783869.

Guan, Xiaohui, et al. “MiR-223 Regulates Adipogenic and Osteogenic Differentiation of Mesenchymal Stem Cells Through a C/EBPs/MiR-223/FGFR2 Regulatory Feedback Loop.” STEM CELLS, vol. 33, no. 5, Wiley-Blackwell, May 2015, pp. 1589–600, doi:10.1002/stem.1947.

Kim, Dong Ki, et al. “Chromatographically Isolated CD63+CD81+ Extracellular Vesicles from Mesenchymal Stromal Cells Rescue Cognitive Impairments after TBI.” Proceedings of the National Academy of Sciences of the United States of America, vol. 113, no. 1, National Academy of Sciences, Jan. 2016, pp. 170–75, doi:10.1073/PNAS.1522297113/SUPPL_FILE/PNAS.201522297SI.PDF.

Logozzi, Mariantonia, et al. “Exosomes: A Source for New and Old Biomarkers in Cancer.” Cancers 2020, Vol. 12, Page 2566, vol. 12, no. 9, Multidisciplinary Digital Publishing Institute, Sept. 2020, p. 2566, doi:10.3390/CANCERS12092566.

Longa, Qianfa, et al. “Intranasal MSC-Derived A1-Exosomes Ease Inflammation, and Prevent Abnormal Neurogenesis and Memory Dysfunction after Status Epilepticus.” Proceedings of the National Academy of Sciences of the United States of America, vol. 114, no. 17, Proc Natl Acad Sci U S A, Apr. 2017, pp. E3536–45, doi:10.1073/PNAS.1703920114.

Monguió-Tortajada, Marta, et al. “Extracellular Vesicle Isolation Methods: Rising Impact of Size-Exclusion Chromatography.” Cellular and Molecular Life Sciences, vol. 76, no. 12, Birkhauser Verlag AG, Mar. 2019, pp. 2369–82, doi:10.1007/S00018-019-03071-Y/METRICS.

Pacienza, Natalia, et al. “In Vitro Macrophage Assay Predicts the In Vivo Anti-Inflammatory Potential of Exosomes from Human Mesenchymal Stromal Cells.” Molecular Therapy - Methods and Clinical Development, vol. 13, no. June, Elsevier Ltd., 2019, pp. 67–76, doi:10.1016/j.omtm.2018.12.003.

Staubach, Simon, et al. “Scaled Preparation of Extracellular Vesicles from Conditioned Media.” Advanced Drug Delivery Reviews, vol. 177, Elsevier, Oct. 2021, p. 113940, doi:10.1016/J.ADDR.2021.113940.

Théry, Clotilde, et al. “Minimal Information for Studies of Extracellular Vesicles 2018 (MISEV2018): A Position Statement of the International Society for Extracellular Vesicles and Update of the MISEV2014 Guidelines.” Journal of Extracellular Vesicles, vol. 7, no. 1, 2018, doi:10.1080/20013078.2018.1535750.

Whiteside, Theresa L. “Tumor-Derived Exosomes and Their Role in Cancer Progression.” Advances in Clinical Chemistry, vol. 74, Adv Clin Chem, 2016, pp. 103–41, doi:10.1016/BS.ACC.2015.12.005.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Elia Bari

4 Sep 2023

Ion exchange chromatography as a simple and scalable method to isolate biologically active small extracellular vesicles from conditioned media

PONE-D-23-17535R1

Dear Dr. Malvicini,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Elia Bari

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does the manuscript report a protocol which is of utility to the research community and adds value to the published literature?

Reviewer #2: Yes

**********

2. Has the protocol been described in sufficient detail?

To answer this question, please click the link to protocols.io in the Materials and Methods section of the manuscript (if a link has been provided) or consult the step-by-step protocol in the Supporting Information files.

The step-by-step protocol should contain sufficient detail for another researcher to be able to reproduce all experiments and analyses.

Reviewer #2: Yes

**********

3. Does the protocol describe a validated method?

The manuscript must demonstrate that the protocol achieves its intended purpose: either by containing appropriate validation data, or referencing at least one original research article in which the protocol was used to generate data.

Reviewer #2: Yes

**********

4. If the manuscript contains new data, have the authors made this data fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the article presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please highlight any specific errors that need correcting in the box below.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: The manuscript has been improved according to the reviewer's comments. The manuscript might be published in PLOS One in its current form.

Sincerely,

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: Yes: Sergey Sedykh

**********

Acceptance letter

Elia Bari

7 Sep 2023

PONE-D-23-17535R1

Ion exchange chromatography as a simple and scalable method to isolate biologically active small extracellular vesicles from conditioned media

Dear Dr. Malvicini:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Elia Bari

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. Ion exchange chromatography protocol for the isolation of extracellular vesicles from conditioned media.

    Step-by-step protocol, also available on protocols.io.

    (PDF)

    S2 File. Materials and methods related to the production, quantification and characterization of the EVs.

    (DOCX)

    S3 File. Raw gel/blots images.

    Uncropped and unadjusted images of the blots for TSG101, calnexin and Cytochrome C and the gels after silver-staining are provided.

    (PDF)

    S4 File. MacsPlex flow cytometry gating strategy.

    A representative gating strategy for the analysis of the different sample is provided.

    (PDF)

    S5 File. MacsPlex flow cytometry raw data.

    Representative RAW data (mean fluorescence intensity) from the MacsPlex analysis from a single experiment is provided.

    (TXT)

    S1 Fig. sEV surface proteins assessment.

    The presence of surface proteins was assessed by flow cytometry using the MACSPlex kit. MSC related proteins are depicted in (A), adhesion molecules are shown in (B) and immunological related proteins are shown in (C).

    (DOCX)

    S1 Table. Size and distribution parameters.

    Mean size, mode, D10, D50 and D90 parameters from the tRPS analysis for fractions 2, 3, 4 and 5.

    (DOCX)

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES